Dakota Wealth Management Has $742,000 Position in Organon & Co. (NYSE:OGN)

Dakota Wealth Management lessened its position in Organon & Co. (NYSE:OGN) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,758 shares of the company’s stock after selling 836 shares during the quarter. Dakota Wealth Management’s holdings in Organon & Co. were worth $742,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Prospera Private Wealth LLC bought a new position in shares of Organon & Co. during the 3rd quarter worth approximately $25,000. Horizon Bancorp Inc. IN boosted its holdings in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares during the last quarter. William B. Walkup & Associates Inc. bought a new position in Organon & Co. in the second quarter valued at $31,000. Versant Capital Management Inc increased its stake in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after buying an additional 1,324 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after buying an additional 672 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Organon & Co. currently has an average rating of “Hold” and a consensus target price of $21.33.

Organon & Co. Trading Down 2.7 %

NYSE OGN opened at $15.97 on Friday. The company has a market cap of $4.11 billion, a PE ratio of 3.17, a PEG ratio of 0.87 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The stock has a 50 day moving average of $15.36 and a 200-day moving average of $18.09. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the company earned $0.78 EPS. Organon & Co.’s quarterly revenue was up 4.1% on a year-over-year basis. On average, equities research analysts anticipate that Organon & Co. will post 3.82 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.01%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.